Metformin targets gastric cancer stem cells

Area of Science:

• Oncology
• Pharmacology
• Cancer Stem Cell Biology

Background:

• Gastric cancer is a leading cause of cancer mortality with a poor prognosis.
• Targeting cancer stem cells (CSCs) presents a novel therapeutic avenue for gastric cancer.
• Metformin is an antidiabetic drug with potential anticancer properties.

Purpose of the Study:

• To evaluate the anti-tumoural effects of metformin on gastric cancer.
• To determine if metformin targets gastric CSCs in vitro and in vivo.
• To assess metformin's impact on CSC proliferation, self-renewal, and differentiation markers.

Main Methods:

• In vitro studies using 2D and 3D cell cultures (tumorsphere assays) with gastric cancer cell lines and patient-derived primary tumor xenografts (PDXs).
• In vivo studies using mouse xenograft models.
• Analysis of cell cycle, CSC markers (CD44, Sox2), and differentiation markers (Kruppel-like factor 4, MUC5AC).

Main Results:

• Metformin induced cell cycle arrest, decreasing proliferation in 2D cultures.
• Metformin reduced tumorsphere formation in 3D cultures, indicating CSC targeting.
• Metformin altered CSC and differentiation marker expression and delayed tumor growth in vivo, reducing CSC self-renewal.

Conclusions:

• Metformin demonstrates significant anti-tumoural effects against gastric cancer.
• Metformin effectively targets gastric cancer stem cells, inhibiting their proliferation and self-renewal.
• Metformin represents a potential therapeutic strategy for gastric cancer by targeting CSCs.